Vessel abnormalization: another hallmark of cancer? Molecular mechanisms and therapeutic implications.

[1]  P. Carmeliet,et al.  HRG inhibits tumor growth and metastasis by inducing macrophage polarization and vessel normalization through downregulation of PlGF. , 2011, Cancer cell.

[2]  D. Nam,et al.  Double antiangiogenic protein, DAAP, targeting VEGF-A and angiopoietins in tumor angiogenesis, metastasis, and vascular leakage. , 2010, Cancer cell.

[3]  C. Betsholtz,et al.  The absence of pericytes does not increase the sensitivity of tumor vasculature to vascular endothelial growth factor-A blockade. , 2010, Cancer research.

[4]  M. Giacca,et al.  Further Pharmacological and Genetic Evidence for the Efficacy of PlGF Inhibition in Cancer and Eye Disease , 2010, Cell.

[5]  Thijs J. Hagenbeek,et al.  PlGF Blockade Does Not Inhibit Angiogenesis during Primary Tumor Growth , 2010, Cell.

[6]  Minhong Yan,et al.  Chronic DLL4 blockade induces vascular neoplasms , 2010, Nature.

[7]  N. Ferrara.  Pathways mediating VEGF-independent tumor angiogenesis. , 2010, Cytokine & growth factor reviews.

[8]  P. Koumoutsakos,et al.  Tumorigenesis and Neoplastic Progression Contrasting Actions of Selective Inhibitors of Angiopoietin-1 and Angiopoietin-2 on the Normalization of Tumor Blood Vessels , 2009 .

[9]  M. Simon,et al.  Endothelial deletion of hypoxia-inducible factor-2alpha (HIF-2alpha) alters vascular function and tumor angiogenesis. , 2009, Blood.

[10]  R. Bicknell,et al.  Anticancer strategies involving the vasculature , 2009, Nature Reviews Clinical Oncology.

[11]  Frederik De Smet,et al.  Branching morphogenesis and antiangiogenesis candidates: tip cells lead the way , 2009, Nature Reviews Clinical Oncology.

[12]  G. Melillo,et al.  Role of the hypoxic tumor microenvironment in the resistance to anti-angiogenic therapies. , 2009, Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy.

[13]  Peter Carmeliet,et al.  Endothelial oxygen sensors regulate tumor vessel abnormalization by instructing phalanx endothelial cells , 2009, Journal of Molecular Medicine.

[14]  R. Jain,et al.  Edema control by cediranib, a vascular endothelial growth factor receptor-targeted kinase inhibitor, prolongs survival despite persistent brain tumor growth in mice. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  C. Betsholtz,et al.  Endothelial-mural cell signaling in vascular development and angiogenesis. , 2009, Arteriosclerosis, thrombosis, and vascular biology.

[16]  Frederik De Smet,et al.  Heterozygous Deficiency of PHD2 Restores Tumor Oxygenation and Inhibits Metastasis via Endothelial Normalization , 2009, Cell.

[17]  Masahiro Inoue,et al.  Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. , 2009, Cancer cell.

[18]  John M L Ebos,et al.  Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis. , 2009, Cancer cell.

[19]  Gavin Thurston,et al.  Control of vascular morphogenesis and homeostasis through the angiopoietin–Tie system , 2009, Nature Reviews Molecular Cell Biology.

[20]  Elisabetta Dejana,et al.  The control of vascular integrity by endothelial cell junctions: molecular basis and pathological implications. , 2009, Developmental cell.

[21]  Holger Gerhardt,et al.  Angiogenesis: a team effort coordinated by notch. , 2009, Developmental cell.

[22]  Peter Carmeliet,et al.  Regulation of angiogenesis by oxygen and metabolism. , 2009, Developmental cell.

[23]  D. Schadendorf,et al.  Angiopoietin-2 Levels Are Associated with Disease Progression in Metastatic Malignant Melanoma , 2009, Clinical Cancer Research.

[24]  D. Schadendorf,et al.  Host-derived angiopoietin-2 affects early stages of tumor development and vessel maturation but is dispensable for later stages of tumor growth. , 2009, Cancer research.

[25]  Christian Fischer,et al.  FLT1 and its ligands VEGFB and PlGF: drug targets for anti-angiogenic therapy? , 2008, Nature Reviews Cancer.

[26]  Jian-Xiong Chen,et al.  Ang-1 Gene Therapy Inhibits Hypoxia-Inducible Factor-1α (HIF-1α)-Prolyl-4-Hydroxylase-2, Stabilizes HIF-1α Expression, and Normalizes Immature Vasculature in db/db Mice , 2008, Diabetes.

[27]  Na Zhang,et al.  Deletion of Vascular Endothelial Growth Factor in myeloid cells accelerates tumorigenesis , 2008, Nature.

[28]  Jianhua Huang,et al.  A Role for VEGF as a Negative Regulator of Pericyte Function and Vessel Maturation , 2008, Nature.

[29]  L. Ellis,et al.  VEGF-targeted therapy: mechanisms of anti-tumour activity , 2008, Nature Reviews Cancer.

[30]  Y. Fujii‐Kuriyama,et al.  Hypoxia-inducible Transcription Factor-2α in Endothelial Cells Regulates Tumor Neovascularization through Activation of Ephrin A1* , 2008, Journal of Biological Chemistry.

[31]  W. Kaelin,et al.  Oxygen sensing by metazoans: the central role of the HIF hydroxylase pathway. , 2008, Molecular cell.

[32]  Fabian Kiessling,et al.  Vascular normalization in Rgs5-deficient tumours promotes immune destruction , 2008, Nature.

[33]  Hua Han,et al.  RBP‐J, the transcription factor downstream of Notch receptors, is essential for the maintenance of vascular homeostasis in adult mice , 2008, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[34]  Lauri Eklund,et al.  Angiopoietins assemble distinct Tie2 signalling complexes in endothelial cell–cell and cell–matrix contacts , 2008, Nature Cell Biology.

[35]  Lei Xu,et al.  Perivascular nitric oxide gradients normalize tumor vasculature , 2008, Nature Medicine.

[36]  Holger Gerhardt,et al.  Pericytes: gatekeepers in tumour cell metastasis? , 2008, Journal of Molecular Medicine.

[37]  Wen Shi,et al.  Delta-like 4 Notch ligand regulates tumor angiogenesis, improves tumor vascular function, and promotes tumor growth in vivo. , 2007, Cancer research.

[38]  F. Soncin,et al.  HIF-2α specifically activates the VE-cadherin promoter independently of hypoxia and in synergy with Ets-1 through two essential ETS-binding sites , 2007, Oncogene.

[39]  M. Giacca,et al.  Anti-PlGF Inhibits Growth of VEGF(R)-Inhibitor-Resistant Tumors without Affecting Healthy Vessels , 2007, Cell.

[40]  L. Ellis,et al.  Overexpression of PDGF-BB decreases colorectal and pancreatic cancer growth by increasing tumor pericyte content. , 2007, The Journal of clinical investigation.

[41]  M Beth McCarville,et al.  Bevacizumab-Induced Transient Remodeling of the Vasculature in Neuroblastoma Xenografts Results in Improved Delivery and Efficacy of Systemically Administered Chemotherapy , 2007, Clinical Cancer Research.

[42]  Gavin Thurston,et al.  Blockade of Dll4 inhibits tumour growth by promoting non-productive angiogenesis , 2006, Nature.

[43]  Minhong Yan,et al.  Inhibition of Dll4 signalling inhibits tumour growth by deregulating angiogenesis , 2006, Nature.

[44]  A. Harris,et al.  Up-Regulation of Endothelial Delta-like 4 Expression Correlates with Vessel Maturation in Bladder Cancer , 2006, Clinical Cancer Research.

[45]  Limor Chen,et al.  Targeted anti-vascular endothelial growth factor receptor-2 therapy leads to short-term and long-term impairment of vascular function and increase in tumor hypoxia. , 2006, Cancer research.

[46]  G. Fong,et al.  Endothelium-Intrinsic Requirement for Hif-2&agr; During Vascular Development , 2005 .

[47]  R. Jain.  Normalization of Tumor Vasculature: An Emerging Concept in Antiangiogenic Therapy , 2005, Science.

[48]  Lei Xu,et al.  Kinetics of vascular normalization by VEGFR2 blockade governs brain tumor response to radiation: role of oxygenation, angiopoietin-1, and matrix metalloproteinases. , 2004, Cancer cell.

[49]  A Jamie,et al.  Branching Morphogenesis , 2004 .

[50]  Rakesh K. Jain,et al.  Vascular Normalization by Vascular Endothelial Growth Factor Receptor 2 Blockade Induces a Pressure Gradient Across the Vasculature and Improves Drug Penetration in Tumors , 2004, Cancer Research.

[51]  Joseph B. Kearney,et al.  The VEGF receptor flt-1 (VEGFR-1) is a positive modulator of vascular sprout formation and branching morphogenesis. , 2004, Blood.

[52]  T. Sjöblom,et al.  Platelet-derived growth factor production by B16 melanoma cells leads to increased pericyte abundance in tumors and an associated increase in tumor growth rate. , 2004, Cancer research.

[53]  Ricky T. Tong,et al.  Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer , 2004, Nature Medicine.

[54]  G. Semenza.  Targeting HIF-1 for cancer therapy , 2003, Nature Reviews Cancer.

[55]  L. Ellis,et al.  Angiopoietin-1 inhibits vascular permeability, angiogenesis, and growth of hepatic colon cancer tumors. , 2003, Cancer research.

[56]  D. Hanahan,et al.  Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors. , 2003, The Journal of clinical investigation.

[57]  N. Glazer,et al.  Angiopoietin-1 protects the adult vasculature against plasma leakage , 2000, Nature Medicine.

[58]  Michal Neeman,et al.  In Vivo Prediction of Vascular Susceptibility to Vascular Endothelial Growth Factor Withdrawal Magnetic Resonance Imaging of C6 Rat Glioma in Nude Mice , 1999 .

[59]  Lieve Moons,et al.  Abnormal blood vessel development and lethality in embryos lacking a single VEGF allele , 1996, Nature.

[60]  R K Jain,et al.  Determinants of tumor blood flow: a review. , 1988, Cancer research.

[61]  C. Heldin,et al.  PDGF and vessel maturation. , 2010, Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer.

[62]  N. Ferrara,et al.  VEGF inhibition: insights from preclinical and clinical studies , 2008, Cell and Tissue Research.

[63]  R. Hill,et al.  The tumor microenvironment and metastatic disease , 2008, Clinical & Experimental Metastasis.

[64]  Tracy T Batchelor,et al.  AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients. , 2007, Cancer cell.